Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Gentiva Health Servcies (NASDAQ: GTIV ) , a provider of home health and hospice care services and solutions, jumped as much as 22% after the company posted better-than-expected first-quarter results before the opening bell.
So what: For the quarter, Gentiva delivered a net revenue increase of 17% to $487.5 million, reflecting gains from its acquisition of Harden Healthcare in October. Home health revenue rose 8% for the quarter to $224.4 million, hospice care revenue decreased 3% to $174.4 million, and community care revenue totaled $57.1 million. Adjusted income, however, dipped to $4.8 million, or $0.13 per share, from $7.1 million, or $0.23 per share, in the year-ago period. Comparatively, Wall Street was looking for a bit more in the top line ($490.6 million), but Gentiva topped EPS by $0.02. More importantly, in spite of Medicare reimbursement drop concerns, Gentiva was able to reaffirm its full-year forecast, which calls for $1.9 billion-$2.1 billion in revenue and $0.85-$1.15 in EPS -- right in line with the current consensus on the Street.
Now what: Gentiva is a tough call for investors. On one hand, there's a defined trend from the Centers for Medicare and Medicaid Services that it's going to continue to push reimbursement rates lower over the long run. Without the aid of acquisitions or out-of-pocket payers, this is going to make growth difficult in select segments for Gentiva. On the other hand, the company is pretty inexpensive at just nine times forward earnings. Of course, even value investors would be wise to account for Gentiva's debt of $1.12 billion, which can act as a hindrance to any significant upside. Overall, I'm leaning slightly toward the optimistic side with Gentiva as it uses its Harden Healthcare acquisition to diversify its operations, but I'd suggest keeping your upside potential expectations in check.
Gentiva shares may have soared today, but it'll likely have a tough time keeping pace with this top stock over the long run
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.